|
A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer. |
|
|
Honoraria - Amgen (I); Bristol-Myers Squibb; Pfizer (I); Roche/Genentech |
Consulting or Advisory Role - Astex Pharmaceuticals; Bayer; Biosceptre; Clovis Oncology; Cybrexa Therapeutics; Ellipses Pharma; Karus Therapeutics; MSD Oncology; Novartis; Octimet; Pierre Fabre; Roche/Genentech |
Speakers' Bureau - Novartis |
Research Funding - AstraZeneca/MedImmune (Inst) |
Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology |
|
Rebecca Sophie Kristeleit |
Honoraria - AstraZeneca; Clovis Oncology; Roche/Genentech; Tesaro |
Consulting or Advisory Role - Basilea; Cerulean Pharma; Clovis Oncology; Roche/Genentech; Sotio |
Travel, Accommodations, Expenses - Basilea; Clovis Oncology; Valirx |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Athenex; Bicycle Therapeutics |
Research Funding - Athenex (Inst); Bristol-Myers Squibb (Inst); Sierra Oncology (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Athenex; BerGenBio; BerGenBio |
|
|
Travel, Accommodations, Expenses - Merck |
|
|
Stock and Other Ownership Interests - RNA Guardian; RNA Guardian (I) |
Speakers' Bureau - Clovis Oncology; OCTIMET |
Research Funding - Incyte (Inst); Nucana (Inst); octimet (Inst); Piqur (Inst); Redx Pharma (Inst); Sierra Pharma (Inst); Tesaro (Inst) |
Patents, Royalties, Other Intellectual Property - WO 2016075455 A1 circulating LARP1 |
Travel, Accommodations, Expenses - Nucana; Tesaro |
|
|
Honoraria - Bristol-Myers Squibb; Eisai; Merck |
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Eisai; Karus Therapeutics |
Research Funding - AstraZeneca (Inst); Basilea (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Lilly (Inst); Merck (Inst); Nutide (Inst); Ono Pharmaceutical (Inst); Roche (Inst); Sierra Oncology (Inst); Verastem (Inst); Vetex Medical (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bayer; Ipsen; Pfizer; Pfizer (I) |
Consulting or Advisory Role - Eisai; Eisai (I); Ipsen (I); Novartis |
Travel, Accommodations, Expenses - Bayer; ipsen; MiNA Therapeutics |
|
|
|
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); MSD (Inst); Sierra Oncology (Inst) |
Travel, Accommodations, Expenses - BMS Brazil; MSD |
|
|
Consulting or Advisory Role - Agalimmune (Inst); Bicycle Therapeutics (Inst); Ellipses Pharma (Inst); EUSA Pharma (Inst); Novartis (Inst); OCTIMET (Inst); Vaccitech (Inst) |
Research Funding - Boston Pharmaceuticals (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Sierra Oncology (Inst); Tioma Therapeutics (Inst); Verastem (Inst) |
Travel, Accommodations, Expenses - Ipsen; Ipsen |
|
|
|
Travel, Accommodations, Expenses - Abbvie; Gilead Sciences |
|
|
No Relationships to Disclose |
|
|
Research Funding - Bayer (Inst) |
|
|
Employment - Sierra Oncology |
Leadership - Sierra Oncology |
Travel, Accommodations, Expenses - Sierra Oncology |
|
|
Employment - Sierra Oncology |
Stock and Other Ownership Interests - Gilead Sciences; Sierra Oncology |
|
|
Employment - Sierra Oncology |
Travel, Accommodations, Expenses - Sierra Oncology |
|
|
Employment - Institute of Cancer Research |
Honoraria - Astellas Pharma; Lilly |
Consulting or Advisory Role - Novartis; Phoenix Solutions |
Research Funding - AstraZeneca (Inst); BTG (Inst); Chugai Pharma (Inst); Onyx (Inst); Verastem (Inst) |
Travel, Accommodations, Expenses - Sierra Oncology |